Amgen Inc. (AMGN)
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
Panagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,025 shares of the medical research company’s stock after selling 899 shares during the period. Panagora Asset Management Inc.’s holdings in Amgen were worth $2,599,000 at the end of the most recent reporting period. Several other institutional investors have also made changes to their positions in AMGN. Briaud Financial Planning Inc bought a new stake in shares of Amgen during the 3rd quarter worth about $26,000. BOK Financial Private Wealth Inc. bought a new stake in Amgen during the fourth quarter worth approximately $29,000. Providence Capital Advisors LLC bought a new position in shares of Amgen in the third quarter valued at approximately $30,000. Planned Solutions Inc. acquired a new stake in shares of Amgen in the fourth quarter worth $30,000. Finally, Delos Wealth Advisors LLC boosted its holdings in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds. Amgen Trading Down 0.7 % Shares of AMGN opened at $312.47 on Monday. The stock’s fifty day simple moving average is $281.36 and its 200-day simple moving average is $284.31. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The firm has a market capitalization of $167.62 billion, a PE ratio of 44.64, a price-to-earnings-growth ratio of 2.81 and a beta of 0.60. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. During the same period in the prior year, the company posted $3.98 EPS. The company’s revenue was up 22.0% compared to the same quarter last year. As a group, research analysts predict that Amgen Inc. will post 19.46 earnings per share for the current year. Amgen Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 128.57%. Analyst Ratings Changes A number of research firms have recently issued reports on AMGN. UBS Group boosted their price objective on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Finally, Morgan Stanley raised their price target on shares of Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $305.65. Check Out Our Latest Analysis on AMGN Insider Buying and Selling at Amgen In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.69% of the company’s stock. Amgen Profile (Free Report) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Read More Five stocks we like better than Amgen Best Aerospace Stocks Investing JD’s Earnings Could Mean Chinese Stocks Making a Comeback CD Calculator: Certificate of Deposit Calculator Canada Goose Flies Higher Driven By DTC Growth 3 REITs to Buy and Hold for the Long Term CVS Health Stock Has a Silver Lining Called Value Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly is generating billions of dollars thanks to its weight loss drugs -- and demand is outpacing supply. Rivals are hoping to carve out share in this high-growth market; Amgen was the latest to report positive news.
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Amgen gets FDA approval for small-cell lung-cancer treatment
Amgen AMGN, -0.65% on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
FDA approves Amgen's treatment for most deadly form of lung cancer
The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.
US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports
The U.S. Food and Drug Administration has granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported on Thursday.
The Best Dividend Stocks For A Dovish Fed
Remember when the Federal Reserve stopped printing money for a few months? It didn't go well.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
